ライフサイエンスコーパス: thymoma

1 R2-IgG dual seropositive patients (one-third thymoma).

2 bodies may expand the serological profile of thymoma.

3 ity of lung, breast, or ovarian carcinoma or thymoma.

4 ty in patients with octreotide scan-positive thymoma.

5 s integrated upstream from c-myc in a second thymoma.

6 usceptible to the spontaneous development of thymoma.

7 CSF and frequently present with a malignant thymoma.

8 ans has been implicated in lympho-epithelial thymoma.

9 for the treatment of patients with advanced thymoma.

10 1957 and 1997 with a pathologic diagnosis of thymoma.

11 second primary malignancies in patients with thymoma.

12 (60.0%) in the second group had a malignant thymoma.

13 nction by distinct mechanisms in suppressing thymoma.

14 n the management of early stage and advanced thymoma.

15 ation are not impaired in the development of thymoma.

16 ure locally advanced, unresectable malignant thymoma.

17 is suggested for patients with unresectable thymoma.

18 s in the management of patients with limited thymoma.

19 rolled, 25 with thymic carcinoma and 16 with thymoma.

20 diagnostic evaluation of patient with cystic thymoma.

21 ndidiasis, ectodermal dystrophy syndrome) or thymoma.

22 receptors), were prevalent in patients with thymoma.

23 apy is well-tolerated and active in relapsed thymoma.

24 derwent complete resection of a stage IVA B3 thymoma.

25 derstand the somatic genetic architecture of thymoma.

26 ut it has not been reached for patients with thymoma.

27 objective was response rate in patients with thymoma.

28 PFS and overall survival than patients with thymoma.

29 is responsible for the development of T cell thymomas.

30 a thymic carcinoma and four were noninvasive thymomas.

31 from supF-tagged proviruses in two resulting thymomas.

32 the more rapid onset and higher incidence of thymomas.

33 in culture and in primary retrovirus-induced thymomas.

34 ing paraneoplastic phenomena associated with thymomas.

35 T cell maturation while going on to develop thymomas.

36 no extensive sequencing has been reported in thymomas.

37 /sec and 1.29 x 10(-3) mm(2)/sec), high-risk thymoma (1.16 x 10(-3) mm(2)/sec and 1.14 x 10(-3) mm(2)

38 both readings (P = .01 and .20) of low-risk thymoma (1.30 x 10(-3) mm(2)/sec and 1.29 x 10(-3) mm(2)

39 ipheral nerve hyperexcitability and 1 with a thymoma; 3 were given immunotherapies.

40 Most of the large lymphomas were thymomas (65%), and these lymphomas developed in less th

41 occur in myasthenia gravis, especially with thymoma, a myopathy associated with Waldenstrom's macrog

42 970T>A) in GTF2I at high frequency in type A thymomas, a relatively indolent subtype.

43 luation revealed the recurrence of malignant thymoma, accompanied by refractory arrhythmia.

44 for TCR gene translocations in p53-deficient thymomas, although abundant aneuploidy involving frequen

45 cloned proviral U3 sequences from the first thymoma and generated an infectious chimeric virus, MCF

46 for malignancy were reclassified as benign (thymoma and histoplasmosis).

47 ia; infections, particularly B19 parvovirus; thymoma and other solid tumors; or a variety of other di

48 patients with histopathologically confirmed thymoma and serum available to test for synaptic autoant

49 ibodies to voltage-gated potassium channels; thymoma and small-cell lung cancer are the most common u

50 le, as well as in subgroups of patients with thymoma and those older than 40 years of age.

51 A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our un

52 9.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively.

53 t any point, which we analysed separately in thymoma and thymic carcinoma cohorts.

54 ifferentiate low-risk thymoma from high-risk thymoma and thymic carcinoma were 1.25 and 1.22 x 10(-3)

55 patients with advanced previously untreated thymoma and thymic carcinoma.

56 49 patients were enrolled (37 with thymomas and 12 with thymic carcinomas) who received a m

57 in culture and in primary retrovirus-induced thymomas and encodes a nuclear, sequence-specific DNA-bi

58 ugmented in tumour endothelium such as mouse thymomas and human lung tumours.

59 e remaining 45 patients had newly-identified thymomas and one had a lymphoma.

60 Five had thymomas and one had an endometrial adenocarcinoma.

61 rmalities and systemic tumours (teratoma and thymoma), and they do not develop SIADH-like hyponatraem

62 Of the 41 patients enrolled, 25 had thymoma, and 16 had thymic carcinoma; patients had a med

63 table adenocarcinoma, melanoma, sarcoma, and thymoma, and also a transgenic model of spontaneous brea

64 pecific CTL to the P815 mastocytoma, the EL4 thymoma, and the Lewis lung carcinoma is dependent on tu

65 = .014) between low-risk thymoma, high-risk thymoma, and thymic carcinoma.

66 Thymomas are infrequent and relatively indolent mediasti

67 The thymomas are monoclonal and highly malignant and display

68 Thymic carcinomas and thymomas are neoplasms of the epithelial cells of the th

69 erologic parallels to APS-I in patients with thymomas are not explained purely by deficient TSAg tran

70 Immune histologic analyses indicate that the thymomas are of epithelial cell origin.

71 ithmic usefulness as negative predictors for thymoma (as recognized for neuronal voltage-gated calciu

72 The mechanisms underlying thymoma-associated immunodeficiency are largely unknown,

73 present the first comprehensive view of a B3 thymoma at whole genome and transcriptome levels.

74 ce which spontaneously and heritably develop thymomas at a very high penetrance.

75 om a proximal Lck promoter construct develop thymomas at an early age, whereas transgenic mice expres

76 as carried a higher number of mutations than thymomas (average of 43.5 and 18.4, respectively).

77 Thymoma behaves as a rather indolent tumor, with most de

78 that multiple lineages of tumors, including thymoma, breast cancer, colon cancer, and melanoma cell

79 mutation in 82% of type A and 74% of type AB thymomas but rarely in the aggressive subtypes, where re

80 0) and B7.2 (CD86) cDNAs into the EL4 T cell thymoma cell line and examined the transfectants for the

81 The EL-4 thymoma cell line contains a peptidase which converts be

82 When expressed in the murine thymoma cell line EL4, activation of this mutant results

83 e coreceptors and their respective mRNA in a thymoma cell line model.

84 line 32Dcl3, and the prolactin-dependent rat thymoma cell line Nb2.

85 n, made by whole cell fusion between a mouse thymoma cell line, and to microcell hybrids made with a

86 Murine thymoma cell lines expressing mutated forms of the mdr1b

87 Sensitive EL4 mouse thymoma cells (s-EL4) respond to phorbol esters with gro

88 Stimulation of sensitive EL4 mouse thymoma cells (s-EL4) with phorbol esters results in pro

89 se the silencer and enhancer in CD4-negative thymoma cells and double-negative immature thymocytes.

90 mitogen-activated protein kinase p38 in EL4 thymoma cells and in freshly isolated murine lymphocytes

91 e Schlafen family members in fibroblasts and thymoma cells either retards or ablates cell growth.

92 in phorbol ester-sensitive EL4 (S-EL4) mouse thymoma cells have been identified as the p120 c-Cbl pro

93 isozyme inhibition were obtained using mouse thymoma cells overexpressing the fas gene (LF(+)).

94 Previous studies of mouse thymoma cells showed that GlcNAc-PI de-N-acetylase activ

95 treated mice bearing tumors derived from EG7 thymoma cells that express the well-characterized chicke

96 e released enzymatically from the surface of thymoma cells transfected with cDNAs encoding TCR-alpha

97 ion against syngeneic, ganglioside GD2+ EL-4 thymoma cells was observed.

98 Incubation of murine thymocytes or S49 mouse thymoma cells with dibutyryl-cAMP, 8-bromo-cAMP, cholera

99 omain and that, unlike the result with mouse thymoma cells, both PIG-L and GlcNAc-PI-de-N-acetylase a

100 In AKR1010 thymoma cells, Nrarp overexpression blocks CBF-1-depende

101 In phorbol ester-sensitive EL4 thymoma cells, phorbol-12-myristate 13-acetate (PMA) ind

102 r but is unable to elongate in CD4(-) CD8(+) thymoma cells.

103 the induction of apoptosis in WEHI7.2 mouse thymoma cells.

104 C57BL/6 mice and fusion of splenocytes with thymoma cells.

105 plex, and their assembly with calnexin in BW thymoma cells.

106 methasone-induced apoptosis of mouse WEHI7.2 thymoma cells.

107 l large granular lymphocytic (LGL) leukemia, thymoma, chronic lymphocytic leukemia, and non-Hodgkin's

108 ese questions based on an index patient with thymoma, chronic visceral leishmaniasis, myasthenia grav

109 In the thymoma cohort, five (14%) of 37 patients (95% CI 5-29)

110 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease.

111 /cAMP pathway was investigated in the murine thymoma-derived T-cell line, EL4.IL-2.

112 Nine (24%) of 37 patients with thymoma developed autoimmune conditions during treatment

113 tion was dispensable for tumorigenesis since thymomas developed with or without the RAG-1 or RAG-2 ge

114 which Notch1IC oncogenes could contribute to thymoma development and maintenance.

115 how that V(D)J recombination is critical for thymoma development in these mice.

116 erological testing as an aid to preoperative thymoma diagnosis.

117 , a strain in which 100% of the mice develop thymoma due to thymocyte-specific inactivation of p53 by

118 eover, expression of a high level of CD80 on thymoma EL4 cells conveys immunity in mice with a target

119 nduction of antitumor immunity to the T cell thymoma, EL4.

120 he overlap of myasthenia, neuromyotonia, and thymoma, emphasizing the importance of appropriate tumor

121 atory for pre-operative evaluation of cystic thymoma, final diagnosis still remains surgical.

122 The available data suggest that thymoma formation in these mice results as a consequence

123 liferative expansion of T cells in vitro and thymoma formation in vivo were prevented by the absence

124 both readings used to differentiate low-risk thymoma from high-risk thymoma and thymic carcinoma were

125 c mice overexpressing the c-myc oncogene and thymomas from mice deficient for the ataxia telangiectas

126 In addition, the thymomas generally express high levels of c-myc.

127 s, B7W-transfected J558 plasmocytoma and EL4 thymoma grow significantly more slowly than those transf

128 tumor-draining lymph nodes (TDLN) during EL4 thymoma growth, this event was insufficient to promote t

129 or unresectable, locally advanced, malignant thymoma has been poor.

130 To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) wit

131 art of the tumor (P = .014) between low-risk thymoma, high-risk thymoma, and thymic carcinoma.

132 otonia as the heralding symptom of recurrent thymoma in a patient with myasthenia gravis.

133 Molecular analyses of the resultant thymomas indicated that the U3 region of MCF ProEn was g

134 hese proviruses are thought to contribute to thymoma induction by enhancer-mediated deregulation of c

135 identified and classified 193 patients with thymoma into 4 groups: (1) lacking neurological autoimmu

136 Cystic thymoma is a rare variant of thymic neoplasm characteriz

137 d syndrome (GS) is a rare condition in which thymoma is associated with hypogammaglobulinemia.

138 Thymoma is commonly recognized in association with paran

139 Thymoma is the most common tumor of the anterior mediast

140 Thymoma is the most common tumor of the anterior-superio

141 cell focus-inducing (MCF) viruses to induce thymomas is determined, in part, by transcriptional enha

142 Molecular pathology of thymomas is poorly understood.

143 TSAgs showed the expected underexpression in thymomas, levels were increased for four of the five TSA

144 est x-ray or computed tomography to rule out thymoma, lymphocyte immunophenotype studies, anti-nuclea

145 ated mutations in this patient suggests that thymomas may evolve through mechanisms distinctive from

146 Of the 193 patients with thymoma, mean patient age was 52 years and did not signi

147 lts were further supported in vivo using EL4 thymoma metastasis as a model of T-cell migration.

148 RNA was translated in the presence of murine thymoma microsomes which, in contrast to the canine panc

149 ulate immunity against tumors in a syngeneic thymoma model.

150 either the pathologic diagnosis (presence of thymoma) nor the age at surgery proved to be negative pr

151 pendent PDAC cells, inactivated c-akt murine thymoma oncogene homolog 1 signaling via mammalian targe

152 required for KRAS activation of c-akt murine thymoma oncogene homolog 1-mammalian target of rapamycin

153 rator-activated receptor gamma, v-AKT murine thymoma oncogene homolog 2, zinc metalloprotease and lip

154 Of 16 patients with thymoma, one (6%, 95% CI 0.2-30.2) had a partial respons

155 r, with most deaths from causes unrelated to thymoma or its direct treatment.

156 ogic diagnosis of limited-stage unresectable thymoma or thymic carcinoma were eligible.

157 Forty-two patients with advanced thymoma or thymic carcinoma were entered onto the trial,

158 Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months

159 d further, we screened 247 patients with MG, thymoma, or both for clinical features and organ-specifi

160 nitially seen with a neoplasm (lung, breast, thymoma, or ovary).

161 Thymoma patients should be monitored for potentially lif

162 relevant acquired T cell immunodeficiency in thymoma patients that is distinct from Good's syndrome.

163 ively, in 49 of 121 (40%) and 10 of 121 (8%) thymoma patients, but clinical features seldom occurred

164 mocyte populations obtained from three other thymoma patients.

165 bearing established TGF-beta-OVA-expressing thymomas, produce high amounts of IFN-gamma and sensitiz

166 entification of gene(s) which participate in thymoma progression, as well as a model system for scree

167 Patient 1 had a thymoma recurrence, but in patient 2 no tumour has been

168 n promoting EG7 (an OVA transfection the EL4 thymoma) rejection in mice.

169 Overall, the thymoma-related mortality rate was 14%; the nonthymoma-r

170 predictors of recurrence and survival after thymoma resection.

171 nt of murine Notch-1 as capable of rendering thymomas resistant to glucocorticoid-induced apoptosis.

172 None of the six patients without pure thymoma responded.

173 patients achieved partial response (both had thymoma; response rate, 8%; 95% CI, 2.2% to 25%), 25 had

174 eristic of APS-I patients, and we assayed 26 thymoma samples for transcripts for AIRE and 16 peripher

175 (AIRE) gene, and myasthenia gravis (MG) with thymoma, show intriguing but unexplained parallels.

176 a case of a 60 year-old woman with a cystic thymoma studied with advanced tomographic imaging stydie

177 of the clonality of preleukemic thymuses and thymomas suggested that the change in pseudotyping chara

178 ngiectasia (AT) patients and in mouse Atm-/- thymoma, suggesting the involvement of V(D)J recombinati

179 sgenes, 100% of the TgTDeltaN mice developed thymoma, surprisingly with reduced latency.

180 ailable for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed

181 as well as a model system for screening anti-thymoma therapeutic agents.

182 oved in four patients (mediastinal teratoma, thymoma, thymic carcinoma and thyroid cancer) and not tr

183 ntraperitoneal challenge with E.G7, the EL-4 thymoma transfected with OVA, results in activation and

184 been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat.

185 lymphocytes (CTL), which lysed melanoma and thymoma tumor cells and inhibited the growth of three un

186 B16/F10.9 murine melanoma, E.G7-OVA, or EL4 thymoma tumors elicited a CTL response to as yet unknown

187 Thymomas vary widely in terms of recurrence and influenc

188 rease in the phosphorylation of v-AKT murine thymoma viral oncogene (AKT) and enhanced the tumorigene

189 ncogenic forms of activation of v-akt murine thymoma viral oncogene homolog (AKT) and NRAS.

190 xpression of activated forms of v-akt murine thymoma viral oncogene homolog (AKT) and Ras in mouse li

191 Activation of v-akt murine thymoma viral oncogene homolog (AKT) and Ras pathways is

192 gnal-regulated kinase (ERK) and v-akt murine thymoma viral oncogene homolog (AKT) in a subset of huma

193 hatidylinositol 3-kinase (PI3K)/v-AKT murine thymoma viral oncogene homolog (AKT) pathway.

194 v akt murine thymoma viral oncogene homolog (AKT) regulation and sign

195 The protein kinase v-akt murine thymoma viral oncogene homolog (AKT), a key regulator of

196 tase and tensin homolog (PTEN), v-akt murine thymoma viral oncogene homolog (AKT), and mammalian targ

197 The kinase v-akt murine thymoma viral oncogene homolog 1 (Akt) and mammalian tar

198 on of PIK3CA by miR-10a reduced V-akt murine thymoma viral oncogene homolog 1 (AKT) phosphorylation a

199 s a major negative regulator of v-akt murine thymoma viral oncogene homolog 1 (AKT).

200 Activated v-AKT murine thymoma viral oncogene homolog 1 (AKT)/protein kinase B

201 protein signalling 4 (RGS4) and V-AKT murine thymoma viral oncogene homolog 1 (AKT1) the data are pro

202 R), the serine/threonine kinase V-Akt murine thymoma viral oncogene homolog 1 (AKT1), and the proteas

203 Sepsis inhibited the V-Akt thymoma viral oncogene homolog 1 and complex 1 of the ma

204 The proline-rich Akt (v-akt murine thymoma viral oncogene homolog 1) substrate of 40 kDa (P

205 ed hyperphosphorylation of AKT (v-akt murine thymoma viral oncogene homolog 1), a phenotype reverted

206 primary liver cancer driven by v-akt murine thymoma viral oncogene homolog and neuroblastoma RAS vir

207 ated a compensatory increase in v-akt murine thymoma viral oncogene homolog signaling and decreased e

208 of miR-155 sensitizes cells to v-akt murine thymoma viral oncogene homolog-1 inhibitors in vitro, su

209 nases such as protein kinase A, v-Akt murine thymoma viral oncogene homolog-1, glycogen synthase kina

210 ta1, protein kinase C-zeta, and v-akt murine thymoma viral oncogene homolog.

211 f the phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene homolog/mammalian target of rapam

212 ic and growth properties of the v-akt murine thymoma viral oncogene homolog/mammalian target of rapam

213 onsistent with this suggestion, v-akt murine thymoma viral oncogene homolog/protein kinase B (AKT/PKB

214 Although AKT1 (v-akt murine thymoma viral oncogene homologue 1) kinase is a central

215 hibits the HGF-induced MET-AKT (v-Akt murine thymoma viral oncogene) signaling pathway and decreases

216 rophic signaling (activation of v-akt murine thymoma viral oncogene/protein kinase B [AKT], inhibitio

217 oupled receptors (GPCRs) activate PI3K/v-AKT thymoma viral oncoprotein (AKT) to regulate many cellula

218 kinase 3beta (Gsk3beta) via inactivation of thymoma viral proto-oncogene (Akt) and 3-phosphoinositid

219 vant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tu

220 n of the insulin receptor substrate 2 (IRS2)-thymoma viral proto-oncogene (Akt) signaling pathway in

221 llular signal-regulated kinase (ERK) and the thymoma viral proto-oncogene (Akt), followed by activati

222 gram during fasting and is then inhibited by thymoma viral proto-oncogene 1 (Akt) after feeding.

223 The U3 region in a tagged LTR in one thymoma was cloned and sequenced.

224 Thymoma was detected in 19 and 11%, respectively, and lu

225 ed small-cell) was found in 77% of patients; thymoma was in 6%.

226 Survival of patients with thymoma was significantly longer than that of patients w

227 Tumors (41.4%), mainly thymomas, were associated with CASPR2 antibodies and a p

228 gressive, complete surgical resection of all thymomas when feasible.

229 ylase inhibitors have shown some activity in thymoma whereas sunitinib may be active in TC.

230 rable with those previously described for B3 thymomas, with CN gain of chromosome 1q, 5, 7 and X and